Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been given an average recommendation of "Moderate Buy" by the sixteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $37.77.

Several equities research analysts have recently issued reports on DNLI shares. JPMorgan Chase & Co. decreased their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a research report on Tuesday, January 7th. Stifel Nicolaus raised shares of Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 price objective for the company in a research report on Monday, December 16th. William Blair reaffirmed an "outperform" rating on shares of Denali Therapeutics in a research report on Friday. Baird R W raised shares of Denali Therapeutics to a "strong-buy" rating in a research report on Tuesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price target for the company.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, insider Carole Ho sold 12,255 shares of Denali Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the transaction, the insider now directly owns 178,580 shares in the company, valued at approximately $3,610,887.60. The trade was a 6.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the transaction, the director now owns 107,976 shares in the company, valued at approximately $2,257,778.16. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,940 shares of company stock worth $973,442. 7.90% of the stock is owned by company insiders.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Polar Asset Management Partners Inc. increased its stake in shares of Denali Therapeutics by 1,240.9% during the fourth quarter. Polar Asset Management Partners Inc. now owns 551,092 shares of the company's stock worth $11,231,000 after acquiring an additional 509,992 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Denali Therapeutics during the fourth quarter worth about $62,000. Woodline Partners LP acquired a new position in shares of Denali Therapeutics during the fourth quarter worth about $2,038,000. Squarepoint Ops LLC increased its stake in shares of Denali Therapeutics by 44.2% during the fourth quarter. Squarepoint Ops LLC now owns 48,619 shares of the company's stock worth $991,000 after acquiring an additional 14,896 shares during the period. Finally, Twinbeech Capital LP acquired a new position in shares of Denali Therapeutics during the fourth quarter worth about $5,188,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Stock Up 4.9 %

DNLI stock traded up $0.75 during midday trading on Friday, hitting $15.95. The company's stock had a trading volume of 2,814,720 shares, compared to its average volume of 1,000,196. Denali Therapeutics has a 52-week low of $14.08 and a 52-week high of $33.33. The firm has a market capitalization of $2.30 billion, a P/E ratio of -5.78 and a beta of 1.43. The firm has a 50-day simple moving average of $21.17 and a 200-day simple moving average of $24.51.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, sell-side analysts expect that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.